Privately held, innovative gene therapy organization using ex vivo and in vivo lentiviral vector-delivered technologies for genetic diseases Senior Vice President, Head of Commercial
▪Selectively recruited by senior executive with full responsibility for Commercial function
▪With $45M 3-year proposed budget, responsible for spearheading integrated Commercialization go-to-market roadmap for gene therapies being developed for rare dermatology and metabolic liver diseases
▪Defined Commercial capabilities and operating structure; positioned organization to attract and retain top talent that shares collective fit-for-purpose, all-hands-on-deck mentality
▪Prepared organization to deploy innovative business solutions, including value-based pricing and reimbursement models, integrative 3-D customer value-chain for autologous (personalized) gene therapies, and enhancing strong community connections to unlock patient/caregiver activation
▪Participated in IR-driven activities, including pres

Taiwan-based biopharma with $950M market cap; start-up U.S. subsidiary to market monopegylated platform for interferon alfa in blood cancers Vice President, US Marketing & Business Intelligence
▪Member of senior executive leadership team reporting to the President & GM of the U.S. subsidiary
▪Y1 revenue of >$90M - developed US Commercialization strategy, commencing with first product launch in Polycythemia Vera—a rare blood cancer; exceeded expectations by >15%
▪Responsibility for oncology marketing, analytics, research, competitive intelligence, new product planning, patient solutions; key partner in payer landscape intel, channel strategy, and specialty pharmacy strategy
▪Partnered with cross-functional leads for rapid expansion of commercial organization to 50+ FTEs in 6-mos

Global biopharma with nearly $5B in annual revenue and $24B market cap driven by innovation and commercialization of rare disease therapies Sr. Director, US Neurology Marketing
▪Led the most successful Alexion launch for Soliris in a rare neuromuscular disease with 60,000 eligible patients
▪Article from Fierce Pharma: Alexion ups 2018 outlook as myasthenia gravis crowned best Soliris launch
▪>$250M was Y1 net revenue; accountable for increased budget of $14.5M
▪Attracted top talent of HCP/Consumer marketers; set vision and purpose to lead initiatives with solid ROI
▪Created investor relations Q&A, participated as Commercial lead stakeholder in Neurology business development deals, led new product planning analyses for newly acquired assets Sr. Director, Germany (Global) Neurology One-year secondment leading German Neurology business
▪Adapted global perspective upon request to join and support highly complex German Neurology market
▪Learned cultural and market differences while c

U.S. specialty pharmaceutical company with $13.5B market cap in 2015; focused on autoimmune & CNS diseases Group Marketing Director, US Neurology Autoimmune & Rare Disease Business
▪Managed >$400M revenue, with 9 FTEs, appointed as Group Director of the US Neurology Rare Disease Business Unit reporting to the VP and General Manager
▪Merged two disparate Neurology marketing business operations to enhance commercial governance and streamline costs within a portfolio of three rare disease brands Product Director, Pain Care Business
▪$17M budget, 80-person cross-functional team to commercialize MNK155— a tamper-deterrent hydrocodone
▪Developed multiple scenarios to evaluate 10-yr brand net present value; led recommendation go to market recommendation plan to Executive Committee with proposal to divest key asset

Global pharmaceutical company with 2013 revenues of $20.3B, market cap of $33B; focused in generic and specialty pharmaceuticals Marketing Associate Director Sr. Product Manager Product Manager, Neurology, Pain, and Oncology
▪3.5 years, 4 brands, 6 indications – Received top performance review rating (i.e. 'Exceeds Expectations) each year
▪Developed operating plan for 3 pre-launch/launch indications; budget accountability up to $12M
▪Led long-range plan, annual operating plan driven by detailed ROI analyses to maximize operating margin Regional Sales Manager
▪Presidents Club Winner during 11-month secondment as field sales leader overseeing Texas region Field Operations/Chief of Staff
▪High visibility role reporting to 3 VPs of Sales totaling >500 FTEs; Received employee top 1% performance award
▪Active participant in leadership reviews of business action plans, incentive compensation programs, and management by objectives (MBOs) to provide holistic ranking driven on behaviors

Global pharmaceutical company with 2005 revenues of $14.5B focused on developing innovative therapies for diabetes, bone and CNS diseases Sales Representative, Neurology and Psychiatry
▪Rookie of the year winner in 2003
▪Field sales trainer